NurExone Biologic Inc. (TSXV:NRX) (FSE:J90), a biopharmaceutical company developing biologically guided exosome therapy for patients with traumatic spinal cord injuries, has announced that it has completed a pre-investigational new drug meeting with the U.S. Food and Drug Administration in connection with the manufacturing, preclinical and clinical development plan of ExoPTEN, NurExone’s first exotherapy product, after receiving a written response from the FDA on Aug. 29.

This is sponsored content issued on behalf of NurExone Biologic Inc., please see full disclaimer here.

Join the discussion: Find out what everybody’s saying about this stock on the NurExone Biologic Inc. Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.

More From The Market Online

MindBio unveils AI-powered fatigue detection breakthrough using voice analytics

MindBio (CSE:MBIO) developed proprietary AI that analyzes speech to detect fatigue and impairment from active substances in real time.

The mental health economy: Investing in the world’s fastest-growing invisible market

Mental health is shifting from a neglected issue to a major economic sector, driven by rising demand, workplace spending, and digital access.The mental health…

2 small-cap stocks built for the long haul

Running a fine-tooth comb through SBC Medical Group and Delta Gold Technologies, two small-cap stocks with solid long-term potential.

Buzz on the Bullboards: Where quarterly reports meet business outlooks

Canadian equities have experienced a volatile stretch over the past week, with both the TSX Composite...